<DOC>
	<DOCNO>NCT02336087</DOCNO>
	<brief_summary>This pilot phase I trial study side effect gemcitabine hydrochloride , paclitaxel albumin-stabilized nanoparticle formulation , metformin hydrochloride , standardize dietary supplement treat patient pancreatic cancer remove surgery . Drugs use chemotherapy , gemcitabine hydrochloride paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Metformin hydrochloride , use diabetes , may also help kill cancer cell . Dietary supplement ( curcumin , vitamin D , vitamin K2 , vitamin K1 , B-6 , high selenium broccoli sprout , epigallocatechin gallate , L-carnitine , garlic extract , genistein , zinc amino chelate , mixed toxopherols , ascorbic acid , D-limonene ) block different target cancer cell simultaneously may slow cancer growth . Giving gemcitabine hydrochloride , paclitaxel albumin-stabilized nanoparticle formulation , metformin hydrochloride dietary supplement may work well treat patient pancreatic cancer remove surgery .</brief_summary>
	<brief_title>Gemcitabine Hydrochloride , Paclitaxel Albumin-Stabilized Nanoparticle Formulation , Metformin Hydrochloride , Standardized Dietary Supplement Treating Patients With Pancreatic Cancer That Can Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess compliance , toxicity feasibility administer gemcitabine ( gemcitabine hydrochloride ) , Abraxane ( paclitaxel albumin-stabilized nanoparticle formulation ) , metformin ( metformin hydrochloride ) , dietary supplement ( DS ) . SECONDARY OBJECTIVES : I . To assess response rate associate combination therapy pancreatic cancer patient . II . To assess progression-free survival overall survival patient start protocol therapy , describe outcome base measure compliance lead-in week , compliance supplement chemotherapy . III . To collect analyze peripheral blood pre-treatment biopsy sample exploratory analysis biological correlative . IV . To assess quality life utilize Functional Assessment Cancer Therapy-General ( FACT-G ) questionnaire . OUTLINE : Patients receive gemcitabine hydrochloride paclitaxel albumin-stabilized nanoparticle formulation intravenously ( IV ) day 1 , 8 , 15 . Patients also receive metformin hydrochloride orally ( PO ) twice daily ( BID ) start day -6 dietary supplement PO BID start day -3 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients must histologic diagnosis pancreatic adenocarcinoma Patient must unresectable disease Patients must receive prior chemotherapy except follow circumstance ; gemcitabine capecitabine chemotherapy give adjuvant setting allow recurrence great 6 month completion chemotherapy ; radiation sensitize dos 5fluororuracil capecitabine allow part adjuvant treatment recurrence must document great 6 month completion adjuvant therapy Computed tomography ( CT ) magnetic resonance imaging ( MRI ) scan must obtain within 4 week prior study entry Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Absolute neutrophil count &gt; 1,500/mcl Platelet count &gt; 100,000/mcl Creatinine &lt; 1.4 mg/dl and/or measure creatinine clearance &gt; 60 cc/min Bilirubin &lt; 1.4 mg/dl Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) great 3.0 time upper limit normal Patients currently treat severe infection recover major surgery intercurrent illnesses ineligible recovery deem complete investigator Patients must pregnant nursing ; woman men reproductive potential must agree use effective contraceptive method All patient must inform investigational nature study must sign give write informed consent accordance institutional federal guideline Patients must able swallow pill must malabsorption problem ongoing nausea vomit would affect oral treatment No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer patient currently complete remission , cancer patient disease free five year Patients currently take metformin eligible Patients allergic egg eligible Patients take additional dietary/herbal supplement ( exclude Senekot ) outside protocol refuse stop eligible Patients require warfarin eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>